It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS or other (non-LCH) dendritic or histiocytic sarcomas cases.
February 9, 2025 at 1:08 AM
July 16, 2025 at 12:26 AM
Big day today- if the MRI is clear, it will be 3 years post stem cell transplant with no brain cancer recurrence! #medulloblastoma #pedsonc. #medsky
Good vibes only, please!
Good vibes only, please!
November 15, 2024 at 6:00 PM
Big day today- if the MRI is clear, it will be 3 years post stem cell transplant with no brain cancer recurrence! #medulloblastoma #pedsonc. #medsky
Good vibes only, please!
Good vibes only, please!
Dr. Maggie Ferris dives into AML biology:
🧬 RXR & KMT2A/C play key roles
⚡️ ATRA works for acute promyelocytic leukemia
💡 MENIN inhibition strategies for MLL-rearranged AML
Can we combine ATRA + Bexarotene?
#LeukemiaResearch #PedsOnc #AML
🧬 RXR & KMT2A/C play key roles
⚡️ ATRA works for acute promyelocytic leukemia
💡 MENIN inhibition strategies for MLL-rearranged AML
Can we combine ATRA + Bexarotene?
#LeukemiaResearch #PedsOnc #AML
May 23, 2025 at 2:47 AM
Dr. Maggie Ferris dives into AML biology:
🧬 RXR & KMT2A/C play key roles
⚡️ ATRA works for acute promyelocytic leukemia
💡 MENIN inhibition strategies for MLL-rearranged AML
Can we combine ATRA + Bexarotene?
#LeukemiaResearch #PedsOnc #AML
🧬 RXR & KMT2A/C play key roles
⚡️ ATRA works for acute promyelocytic leukemia
💡 MENIN inhibition strategies for MLL-rearranged AML
Can we combine ATRA + Bexarotene?
#LeukemiaResearch #PedsOnc #AML
Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets [PODCAST 41 min] #Lymphoma #PedsOnc open.spotify.com/show/1O2rn5W...
Blood Podcast
Podcast · American Society of Hematology · The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.
open.spotify.com
June 25, 2025 at 6:57 PM
Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets [PODCAST 41 min] #Lymphoma #PedsOnc open.spotify.com/show/1O2rn5W...
Peds-AYA survivors, now older teens-young adults who then became parents of #pedsonc patients. My daughter inherited a germ line mutation from me. Its interesting to see the first waves of high survival grow up and have their own kids. Wondering about the changes in stats for inherited risk.
July 16, 2025 at 12:31 AM
Peds-AYA survivors, now older teens-young adults who then became parents of #pedsonc patients. My daughter inherited a germ line mutation from me. Its interesting to see the first waves of high survival grow up and have their own kids. Wondering about the changes in stats for inherited risk.
Grateful for the kind responses to my KevinMD piece. Writing about humor, language, and connection in medicine reminded me that joy it’s a skill we can all practice.
📖 If you missed it: kevinmd.com/2025/08/how-humor-builds-trust-in-pediatric-oncology.html
#JoyInMedicine #MedicalHumanism #PedsOnc
📖 If you missed it: kevinmd.com/2025/08/how-humor-builds-trust-in-pediatric-oncology.html
#JoyInMedicine #MedicalHumanism #PedsOnc
How humor builds trust in pediatric oncology
A pediatric oncologist shares how humor, language slips, and authentic connection help bring light and trust to patients and families facing cancer.
kevinmd.com
August 12, 2025 at 2:59 PM
Grateful for the kind responses to my KevinMD piece. Writing about humor, language, and connection in medicine reminded me that joy it’s a skill we can all practice.
📖 If you missed it: kevinmd.com/2025/08/how-humor-builds-trust-in-pediatric-oncology.html
#JoyInMedicine #MedicalHumanism #PedsOnc
📖 If you missed it: kevinmd.com/2025/08/how-humor-builds-trust-in-pediatric-oncology.html
#JoyInMedicine #MedicalHumanism #PedsOnc
Practice-changing pediatric oncology data from #ASCO26! 🚨
Results from the phase II multicenter RMS13 trial reveal a critical disparity in risk-adapted radiotherapy (RT) for high-risk metastatic rhabdomyosarcoma (#RMS).
Full article: https://bit.ly/4x2Zy7X
#PedsOnc #Sarcoma #ASCO2026
Results from the phase II multicenter RMS13 trial reveal a critical disparity in risk-adapted radiotherapy (RT) for high-risk metastatic rhabdomyosarcoma (#RMS).
Full article: https://bit.ly/4x2Zy7X
#PedsOnc #Sarcoma #ASCO2026
June 2, 2026 at 1:56 PM